Boehringer Ingelheim, a pharmaceutical company has presented information about a study they have been conducting, to evaluate the safety and efficacy of a drug, nintedanib when combined with pemetrexed and ciplatin, to treat pleural mesothelioma.
The study has so far looked at 87 patients with unresectable malignant, pleural mesothelioma assigned to either the nintedanib, pemetrexed and cisplatin combination or a placebo with pemetrexed and cisplatin.
Last month, the LUME-Meso Phase II trial met its primary endpoint of progression-free survival (PFS). The nintedanib, pemetrexed and cisplatin combination demonstrated “a meaningful clinical benefit” compared to placebo plus pemetrexed/cisplatin, with a significantly improved PFS (9.4 vs 5.7 months…). Preliminary overall survival (OS) data also favoured nintedanib (18.3 vs 14.5 months…).
The study is now moving into the next phase, LUMO-Meso Phase III. This is another double blind, randomised study for patients with unresectable malignant pleural mesothelioma. They are currently recruiting participants and hope to find 450 patients across 27 countries.
If you require assistance in pursuing a mesothelioma claim or believe you have a valid asbestos claim for any other asbestos disease, then please contact us today on our freephone number 0800 038 6767. Alternatively, head over to the ‘Contact Us’ page, complete the form and we will be in touch.
Source: Grosso F et al., Nintedanib plus pemetrexed/cisplatin in patients with MPM: Phase II findings from the placebo-controlled LUME-Meso trial. Oral presentation at 17th IASLC World Conference on Lung Cancer Abstract (ID #4191 Oral abstract #OA22.02) Vienna, 4 December 2016